First time available for research use

IL-6 R-antibody

Tocilizumab antibody from RoActemra®

Therapeutic IL-6 R-antibody from the original RoActemra® commercial drug targeting the IL-6 R-antigen, also referred to as RoActemra® or tocilizumab antibody. Research-relevant quantities are available as licence-free consumable in aliquoted or diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments, biosimilar developers can order different batches at the same time.

Choose your antibody
Easy Access

Easy Access

Easy to order as license-free research consumable
Multiple batches

Multiple batches

Up to 10 batches of original drugs for examining batch-to-batch variations
Reduce costs

Reduce costs

Up to 80% less compared to the original pharmaceutical price
Prompt delivery

Prompt delivery

Shipment within days worldwide according to GDP-standards
Documented origin

Documented origin

Information on batch, registration number, expiry date, GDP-compliant pedigree

What our clients say

Tocilizumab/ RoActemra

Product Reference

Drug nameRoActemra®
API typehumanised IgG1 monoclonal antibody against the human interleukin-6 (IL-6) receptor produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology
Pharmacotherapeutic group
Immunosuppressants, Interleukin inhibitors
ATC code
Target of antibody
IL-6 R; Synonyms: IL6R, il-6ra, CD126, IL-6R-1, IL-6RA, IL6Q, IL6RA, IL6RQ, gp80, IL6R1, Il6ra, IL-6Ralpha, IL6R, Il6r
General function
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R). Tocilizumab has been shown to inhibit sIL-6R and mIL-6R-mediated signalling. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, monocytes and fibroblasts. IL-6 is involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, induction of hepatic acute phase protein synthesis and stimulation of haemopoiesis. IL-6 has been implicated in the pathogenesis of diseases including inflammatory diseases, osteoporosis and neoplasia.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)In clinical studies with tocilizumab, rapid decreases in CRP, erythrocyte sedimentation rate (ESR) and serum amyloid A (SAA) were observed. Consistent with the effect on acute phase reactants, treatment with tocilizumab was associated with reduction in platelet count within the normal range. Increases in haemoglobin levels were observed, through tocilizumab decreasing the IL-6 driven effects on hepcidin production to increase iron availability. In tocilizumab-treated patients, decreases in the levels of CRP to within normal ranges were seen as early as week 2, with decreases maintained while on treatment.
In healthy subjects administered tocilizumab in doses from 2 to 28 mg/kg, absolute neutrophil counts decreased to their lowest 3 to 5 days following administration. Thereafter, neutrophils recovered towards baseline in a dose dependent manner. Rheumatoid arthritis patients demonstrated a similar pattern of absolute neutrophil counts following tocilizumab administration (see section 4.8).
Original license holder
Marketing authorisation numbers
EU/1/08/492/001 - 008
Marketing authorisation holder
Roche Registration Limited
6 Falcon Way
Shire Park
Welwyn Garden City
United Kingdom
Name of the manufacturer of the biological active substance
Chugai Pharma Manufacturing Co., Ltd.
16-3 Kiyohara Kogyodanchi
Utsunomiya City
Tochigi, 321-3231

Genentech Inc.
One Antibody Way
CA 92056
Name and address of the manufacturer(s) responsible for batch releaseRoche Pharma AG
Emil-Barell-Strasse 1
D-79639 Grenzach-Wyhlen
Max shelf life
30 months
Storage conditions
2°C – 8°C
List of excipients
Polysorbate 80
Disodium phosphate dodecahydrate
Sodium dihydrogen phosphate dihydrate
Water for injections